SCHEMBL24391579

SCHEMBL24391579

COc1cc2c(C(C)C)nn(CCOc3cc4c(=O)n(C)c(C#N)c(C(C)C)c4cc3OC)c(=O)c2cc1OC

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.32
▸ PDE3B Q13370 1/20 0.32
▸ PDE3A Q14432 1/20 0.32
▸ MAPT P10636 3/20 0.32
▸ LMNA P02545 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ CYP2C9 P11712 1/20 0.31
▸ GRM2 Q14416 1/20 0.31
▸ SRC P12931 8/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NSD2 O96028 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ USP2 O75604 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ CASP1 P29466 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24392086 0.89 SMN1; SMN2 (0.36) TNFPDE3BPDE3AMAPTLMNA
SCHEMBL11548628 0.73 SMN1; SMN2 (0.38) TNFPDE3BPDE3ASMN1; SMN2HPGD
SCHEMBL24393059 0.67 TNF (0.45) TNFPDE3BPDE3AMAPTLMNA
SCHEMBL11547286 0.58 TNF (0.38) TNFMAPTLMNAKMT2AHPGD
SCHEMBL24392642 0.57 EGFR (0.60) SRCEGFR
SCHEMBL11550575 0.57 TNF (0.38) TNFPDE3BPDE3ALMNAKMT2A
SCHEMBL24076916 0.57 LMNA (0.42) MAPTLMNAMEN1KMT2AKDM4E
SCHEMBL24392127 0.57 PDE10A (0.41) PDE3BPDE3AEGFRKDR
SCHEMBL24076941 0.56 NLRP3 (0.46) TSHR
SCHEMBL27359869 0.56 PDE10A (0.47) SRCSMN1; SMN2NSD2KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220135598-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2022-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135598-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, ENPP2 TNF 3089/4885PDE3B 20/4885PDE3A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback